Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects

Drug Metabolism and Disposition

Volumn 32, Issue 5, 2004, Pages 566-571

  Mangold, James B ^a   Gu, Helen ^a   Rodriguez, Lolita C ^a   Bonner, Johanne ^b   Dickson, Janet ^c   Rordorf, Christiane ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Pharmaceut Research Centre   (United Kingdom)

^c Inveresk Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LUMIRACOXIB;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG METABOLISM; FECES ANALYSIS; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; URINALYSIS; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; DICLOFENAC; FECES; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORGANIC CHEMICALS;

EID: 2042475404     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.5.566     Document Type: Article

References (25)

1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al.; VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520-1528.
2. Bonner J, Branson J, Milosavljev S, Rordorf C, and Scott G (2003) Co-administration of lumiracoxib and warfarin does not alter the pharmacokinetic profile of R- or S-warfarin. Ann Rheum Dis 62 (Suppl. 1):264 (Abstract FRI0225).
3. Bruno R, Iliadis A, Jullien I, Guego M, Pinhas H, Cunci S, and Cano JP (1988) Naproxen kinetics in synovial fluid of patients with osteoarthritis. Br J Clin Pharmacol 26:41-44.
4. Crofford LJ (1997) COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 24 (Suppl. 49):15-19.
5. Day RO, McLachlan AJ, Graham GG, and Williams KM (1999) Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 36:191-210.
6. Flower RJ (2003) The development of COX2 inhibitors. Nat Rev Drug Discov 2:179-191.
7. Fu JY, Masferrer JL, Seibert K, Raz A, and Needleman P (1990) The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265:16737-16740.
8. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, and Geis GS (2001) Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 96:1019-1027.
9. Grillo MP and Hua F (2003) Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile. Drug Metab Dispos 31:1429-1436.
10. Grillo MP, Knutson CG, Sanders PE, Waldon DJ, Hua F, and Ware JA (2003) Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile. Drug Metab Dispos 31:1327-1336.
11. Hartmann S, Scott G, Rordorf C, Campestrini J, Branson J, and Keller U (2003) Lumiracoxib demonstrates high absolute bioavailability in healthy subjects, in European Collaboration: Towards Drug Development and Rational Drug Therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics 2003 June-24-28; Istanbul (Tulunay FC and Orme M, eds) p. 124 (Abstract P-199), Springer-Verlag, Berlin.
12. Hernandez-Diaz S and Garcia-Rodriguez LA (2001) Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 110 (Suppl. 3A):20S-27S.
13. Hinson JA and Forkert PG (1995) Phase II enzymes and bioactivation. Can J Physiol Pharmacol 73:1407-1413.
14. Kalbag J, Scott G, Yeh C-M, Gurrierie P, Milosavljev S, and Rordorf C (2002) Lumiracoxib pharmacokinetics remain unchanged between subjects with a moderate degree of hepatic impairment and healthy subjects. J Clin Pharmacol 42:1051-1071 (Abstract 17).
15. Marshall PJ, Berry JC, Wasvary J, van Duzer J, Du Z, Scott G, Rordorf C, Milosavljev S, and Fujimoto RA (2002) The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2. Ann Rheum Dis 61 (Suppl. 1):259 (Abstract SAT0013).
16. Rainsford KD, Schweitzer A, and Brune K (1981) Autoradiographic and biochemical observations on the distribution of non-steroid anti-inflammatory drugs. Arch Int Pharmacodyn Ther 250:180-194.
17. Reynolds C, Scott G, Looby M, Milosavljev S, Huff JP, Ruff DA, and Rordorf C (2003) Pharmacokinetics of lumiracoxib in synovial fluid and plasma of patients with rheumatoid arthritis, in European Collaboration: Towards Drug Development and Rational Drug Therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics; 2003 June-24-28; Istanbul (Tulunay FC and Orme M, eds) p. 123 (Abstract P-195), Springer-Verlag, Berlin.
18. Rordorf C, Scott G, Milosavljev S, Blood P, Branson J, and Greig G (2002) Steady state pharmacokinetics, pharmacodynamics, safety and tolerability of COX189 in healthy subjects. Ann Rheum Dis 61 (Suppl. 1):420 (Abstract AB0284).
19. Scott G, Branson J, Milosavljev S, Rordorf C, Haraoui B, Ouellet J-P, and Schell E (2003a) Lumiracoxib demonstrates dose-proportional and time-independent pharmacokinetics in patients with osteoarthritis of the knee. Ann Rheum Dis 62 (Suppl. 1):267 (Abstract FRI0235).
20. Scott G, Rordorf C, Blood P, Branson J, Milosavljev S, and Greig G (2002a) Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Ann Rheum Dis 61 (Suppl. 1):242 (Abstract FR10300).
21. Scott G, Rordorf C, Milosavljev S, Chase W, Fleischmann R, and Kivitz A (2003b) Multiple-dose lumiracoxib shows rapid absorption and COX-2 selectivity without accumulation in patients with rheumatoid arthritis, in European Collaboration: Towards Drug Development and Rational Drug Therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics; 2003 June-24-28; Istanbul (Tulunay FC and Orme M eds), p. 124 (Abstract P-197). Springer-Verlag, Berlin.
22. Scott G, Rordorf C, Milosavljev S, and Ferber G (2002b) Pharmacokinetics and pharmacodynamics of COX189 in patients with knee or hip primary osteoarthritis Ann Rheum Dis 61 (Suppl. 1):128 (Abstract THU0233).
23. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, and Vane JR (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 9:7563-7568.
24. Wilding IR, Connor AL, Carpenter P, Rordorf C, Branson J, Milosavljev S, and Scott G (2004) Lumiracoxib shows similar bioavailability at different sites in the gastrointestinal tract. Pharm Res (NY) 21:443-446.
25. Yih L, Scott G, Yeh C-M, Milosavljev S, Laurent A, and Rordorf C (2003) Fluconazole does not affect lumiracoxib pharmacokinetics in healthy subjects: a two-stage, open-label, randomized, crossover study, in European Collaboration: Towards Drug Development and Rational Drug Therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. (Tulunay FC and Orme M eds) Berlin: Springer-Verlag; p. 123 (Abstract P-194).